NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

COVID-19 Vaccine Biomarker Study in Multiple Sclerosis

CompletedN/A

Sponsor: Columbia University

Conditions: Multiple Sclerosis, COVID-19

Countries: United States

SARS CoV-2 is the virus responsible for the pandemic COVID-19, which has resulted in nearly five million deaths worldwide since its spread in the beginning of 2020. In the United States, there are now two emergency use authorized vaccines that make use of messenger ribonucleic acid (mRNA) based technology that are highly effective for preventing COVID. However, because multiple sclerosis is an autoimmune condition, many individuals with multiple sclerosis take medicines that affect the immune system. The investigators are not sure whether individuals on certain MS medications, including medications that lower a type of immune cell called B lymphocytes, will form as robust of a response to the vaccines. In this study, the investigators will be gathering more information about effectiveness of these vaccines and bloodwork that looks at antibodies and other markers of vaccine response and by asking patients about COVID-19 infections.

Eligibility overview

Sex: ALL

Age: 18 Years to 70 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of any form of multiple sclerosis based on 2017 McDonald Criteria
* Ages 18 to 70
* No history of prior vaccination against SARS-CoV-2 at the start of the study

Exclusion Criteria:

* Unable to obtain blood draws at predetermined time points
* Pregnant at time of enrollment or planning pregnancy during upcoming 6 month period after vaccination

Locations (1)

New York, New York, United States